Background Microcystic macular oedema (MMO) of the retinal inner nuclear layer (INL) has been identifi ed in patients with multiple sclerosis (MS) by use of optical coherence tomography (OCT). We aimed to determine whether MMO of the INL, and increased thickness of the INL are associated with disease activity or disability progression. Methods This retrospective study was done at the Johns Hopkins Hospital (Baltimore, MD, USA), between September, 2008, and March, 2012. Patients with MS and healthy controls underwent serial OCT scans and clinical assessments including visual function. OCT scanning, including automated intraretinal layer segmentation, yielded thicknesses of the retinal nerve fi bre layer, the ganglion cell layer plus inner plexiform layer, the INL plus outer plexiform layer (the combined thickness of these layers was used as a surrogate measure of INL thickness), and the outer nuclear layer. Patients with MS also underwent annual brain MRI scans. Disability scores were compared with the Wilcoxon ranksum test. Mixed-eff ects linear regression was used to compare OCT measures and letter-acuity scores. Logistic regression was used to examine the relations of baseline OCT thicknesses with clinical and radiological parameters. Findings 164 patients with MS and 60 healthy controls were assessed. Mean follow-up was 25·8 months (SD 9·1) for patients with MS and 22·4 months (11·4) for healthy controls. Ten (6%) patients with MS had MMO during at least one study visit; MMO was visible at baseline in four of these patients. Healthy controls did not have MMO. Patients with MS and MMO had higher baseline MS severity scores (median 5·93 [range 2·44-8·91]) than those who did not have MMO at any time during the study (151 patients; 3·81 [0·13-9·47]; p=0·032), although expanded disability status scale (EDSS) scores were not signifi cantly diff erent (5·2 [1·0-6·5] for patients with MS and MMO vs 2·5 [0·0-8·0] for those without MMO; p=0·097). The eyes of patients with MS and MMO (12 eyes) versus those without MMO (302 eyes) had lower letter-acuity scores (100% contrast, p=0·017; 2·5% contrast, p=0·031; 1·25% contrast, p=0·014), and increased INL thicknesses (p=0·003) at baseline. Increased baseline INL thickness in patients with MS was associated with the development of contrast-enhancing lesions (p=0·007), new T2 lesions (p=0·015), EDSS progression (p=0·034), and relapses in patients with relapsing-remitting MS (p=0·008) during the study. MMO was not associated with disease activity during follow-up. Interpretation Increased INL thickness on OCT is associated with disease activity in MS. If this fi nding is confi rmed, INL thickness could be a useful predictor of disease progression in patients with MS.
Introduction
Multiple sclerosis (MS) is often regarded as an immunemediated infl ammatory demyelinating disorder of the CNS, in which neurodegeneration is a secondary phenomenon. 1 Grey-matter degeneration is, however, common in MS and more closely associated with disability than white-matter degeneration. 2, 3 Whether grey-matter degeneration in MS occurs only as a result of white-matter injury is unclear. 4 Neuronal loss in the retina could occur as a primary process in MS, independent of demyelination or axonal injury. 5, 6 The retina, although unmyelinated, is a common site of infl ammation, disruption of the blood-retina barrier, and neuronal loss in patients with MS. Retinal perivascular infl ammation (periphlebitis), suggesting disruption of the blood-retina barrier, occurs in up to 20% of patients with MS. 7 Active retinal periphlebitis tends to occur simultaneously with disruption of the blood-brain barrier in these patients, 8 and might be a risk factor for relapses and gadolinium-enhancing lesions. 9 Intermediate uveitis, especially pars planitis, also occurs in up to 16% of patients with MS. 10 Consistent with clinical observations, postmortem analyses show retinal infl ammation with activated microglia in the eyes of people with MS. 11 Collectively, these fi ndings suggest myelin might not be necessary for maintaining or propagating infl ammation in MS.
Spectral-domain optical coherence tomography (OCT) renders images with high resolution (<5 μm), 12 from which the individual retinal layers can be demarcated, qualitatively assessed, and objectively and precisely quantifi ed. 5 These layers in clude the retinal nerve fi bre layer (RNFL), ganglion cell layer (GCL), inner nuclear layer (INL), and outer nuclear layer (ONL). The RNFL is the innermost layer of the retina and primarily consists of the axons of ganglion cell neurons, which are located distal to the RNFL. These axons coalesce at the optic disc to form the optic nerve, and exit the eye through the lamina cribrosa, where they acquire myelin. 6 MS aff ects the optic nerves both clinically (as optic neuritis) and subclinically, resulting in retro grade degeneration of the axons of the optic nerve, culminating in RNFL and GCL atrophy 7, 11, 13 that can be detected and quantifi ed in vivo with OCT. 6, 14 Additionally, deeper retinal layer pathology has been shown to occur in MS, although not in all studies. 15 Consistent with postmortem demonstration of INL atrophy in 40% of eyes of patients with MS, 11 and the electroretinographic identifi cation of INL and ONL dysfunction, 16, 17 we have previously shown using macular segmentation that INL and ONL thicknesses are decreased in eyes of patients with MS, both with optic neuritis (which we have termed mixed retinal pathology phenotype) and without a history of optic neuritis (which we have termed macular thinning predominant phenotype). 5, 6 These fi ndings could represent primary retinal neuronal mechanisms of pathology, since atrophy of the INL or ONL has not been shown following optic nerve transection in animals. 18 The presence of this deeper retinal neuronal layer pathology in patients with MS was associated with greater disability in a cross-sectional study. 5 A recent study using OCT identifi ed microcystic macular oedema (MMO) of the INL in about 5% of patients with MS. 19 MMO was thought to represent breakdown of the blood-retina barrier and retinal infl ammation, potentially because of subclinical uveitis or retinitis, and was associated with greater disability and visual dysfunction. However, longitudinal data were available for only six patients, and the INL was not quantitatively assessed with OCT segmentation. There fore, the prevalence of MMO of the INL, and its develop ment over time in patients with MS remains unclear. Since MMO of the INL might be infl ammatory, we postulate that some patients with MS could harbour INL infl ammation in the absence of visible MMO, resulting in increased thickness of the INL. Indeed, a recent cross-sectional study showed that increased thickness of the INL (measured as the thickness of the combined INL and outer plexiform layer) correlated with higher T2-weighted fl uid-attenuated inversion recovery MRI lesion volume in patients with MS, while thicknesses of other retinal layers did not. 20 The clinical relevance of MMO of the INL and increased INL thickness (which could both represent myelin-independent neuronal compartment infl am mation) remains to be elucidated.
The primary objectives of our retrospective study were: (1) to confi rm the occurrence of MMO in patients with MS, ascertain its prevalence, and assess whether MMO occurs in healthy controls (to determine whether MMO in patients with MS represents a pathological process or a normal phenomenon); (2) to determine whether MMO in patients with MS is associated with disease activity and disability; and (3) to determine whether increased thickness of the INL at baseline, measured as thickness of the combined INL and outer plexiform layer, in patients with MS is associated with disease activity or disability progression.
Methods

Study design and participants
Two cohorts were recruited: an MS cohort (without acute optic neuritis or evidence of optic disc swelling on fundoscopy within 3 months of baseline assessment; about 40% of this cohort have been included in other cross-sectional studies done by our group) and a healthy control cohort. 6, 20 Study participants were recruited between September, 2008, and December, 2010, and studied between September, 2008, and March, 2012.
The MS cohort was recruited by unselected convenience sampling of consecutive eligible patients from one centre (Johns Hopkins MS Center, Baltimore, MD, USA). MS diagnosis was con fi rmed by the treating neurologist (PAC) on the basis of the 2010 revised McDonald criteria. 21 Patients who had acute optic neuritis during follow-up (which can con found OCT measures owing to oedema), and patients with diabetes, uncontrolled hypertension, glaucoma, refractive errors of more or less than six dioptres, or other ophthalmological or neuro logical disorders were excluded from the study.
Participants in the control group without known ocular disease, refractive errors of more or less than six dioptres, or neurological disease were recruited from among Johns Hopkins University staff , and invited for annual OCT scans; some of these participants have been included in previous studies done by our group. 6, 20 Johns Hopkins University staff members live in a similar geographic area as our patient population, and were chosen to have a similar range of ages (18-65 years) and sex ratio (roughly 70% female) as in a typical cohort of patients with MS, as well as for their willingness to return for repeat OCT scanning.
The Johns Hopkins University Institutional Review Board approval was acquired and written informed consent was obtained from all participants before study enrolment.
Procedures
Patients with MS underwent clinical assessment and OCT every 6 months and brain MRI annually. Retinal imaging was done with spectral-domain Cirrus HD-OCT (model 4000, software version 5.0; Carl Zeiss Meditec, Dublin, CA, USA), as described in detail elsewhere. 5, 6 Briefl y, peripapillary and macular scans were obtained with the Optic Disc Cube 200×200 and Macular Cube 512×128 protocols, respectively. Scans with signal strength less than 7/10 or with artifacts were excluded from analyses.
Macular cube scans were analysed in a masked fashion with segmentation software, as described in detail elsewhere. 6 Briefl y, segmentation undertaken in three dimensions yields the thicknesses of the following macular layers: the RNFL, GCL and inner plexiform layer (GCIP), INL including the outer plexiform layer, and ONL including inner and outer photoreceptor segments. The retinal segmentation technique that we used has not yet been extended to separate the INL from the neighbouring outer plexiform layer; therefore, the combined thickness of these two layers is used as a surrogate of INL thickness. This segmentation protocol has been shown to be reproducible in MS and control groups (inter-rater intraclass correlation coeffi cients: 0·91-0·99 for all segmentation measurements; 0·94 in the MS group and 0·91 in the control group for the INL including the outer plexiform layer). 5 All macular cube scans were qualitatively assessed for MMO or other retinal abnormalities by two reviewers masked to clinical and radiological status (SS and ESS). MMO was defi ned as cystic, lacunar areas of hyporefl ectivity with clear boundaries, evident on at least two contiguous B scans, or visible in a comparable region on at least two separate acquisitions. Scans designated as fulfi lling MMO criteria or showing other retinal abnormalities by either reviewer were reviewed and verifi ed by a retinal specialist, masked to clinical status (QDN). MS disease subtype was classifi ed as relapsingremitting (RRMS), secondary progressive (SPMS), or primary progressive MS (PPMS). Disease duration, comorbidities, and history of optic neuritis, including the date and side of occurrence, were recorded. Expanded disability status scale (EDSS) scores were determined by Neurostatus-certifi ed EDSS examiners (SS, JNF, JO, SDN, PAC) at study visits (within 30 days of OCT or MRI examinations). Baseline disease duration and EDSS scores were used to assess participants' baseline MS severity score (MSSS). Disability progression was defi ned as a 1 point or more, or a 0·5 point or more increase in EDSS score from baseline to end-of-study EDSS examination, respectively, if the baseline EDSS score was less than six or six or more. Ocular (optic neuritis) and nonocular relapses during follow-up were verifi ed and recorded.
Standardised 100% high-contrast, 2·5% low-contrast, and 1·25% low-contrast letter-acuity scores were determined at study visits with retroilluminated eye charts, as described in detail elsewhere. 6, 14 High-contrast (100%) and low-contrast (2·5% and 1·25%) visual loss were defi ned as a decrease of fi ve or more letters or seven or more letters, respectively, during follow-up, in accordance with published data. 14 Brain MRI was done with a 3 T Philips Intera scanner (Philips Medical System, Best, Netherlands). The following axial, whole-brain sequences were acquired: double-echo fast-spin-echo to obtain T2-weighted scans (acquired resolution 1·1×1·1×2·2 mm; echo time 12 ms and 80 ms; repetition time 4169 ms; sensitivity encoding factor 2; repetitions 1) and a T1-weighted gadoliniumenhanced scan (acquired resolution 0·9×0·9×3·0; echo time 10 ms; repetition time 0·5 s). The same scanner and sequence protocols were used at each study visit. Contrast-enhancing lesions (at baseline and during follow-up) and new T2-hyperintense lesions (defi ned as the development of one or more T2-hyperintense lesions during follow-up, not evident on baseline imaging) were recorded by a reviewer (SS) masked to both clinical and OCT status.
Statistical analysis
Statistical analyses were done with Stata (version 11.0). The Shapiro-Wilk test was used to assess normality of distributions. Comparisons between groups were done with the Wilcoxon rank-sum test (for disease duration, EDSS, and MSSS; these variables were not normally distributed), Student's t test (for age; normally distributed), and χ² test (for optic neuritis history, sex, immunomodulatory treatment, clinical and radiological disease activity, and proportions of MS subtype). Mixed-eff ects linear regression, accounting for withinsubject inter-eye correlations, was used to compare OCT meas ures and letter-acuity scores between groups. Logistic regression with robust SE, accounting for within-subject inter-eye correlations, was used to examine the relations of baseline INL thicknesses with clinical and radiological parameters. Multivariate models were adjusted for age and sex in comparisons of patients with MS with healthy controls, and also disease duration and history of optic neuritis in analyses between MS subgroups. Levene's variance ratio testing was used to assess diff erences in INL thickness variance by disease duration. Statistical signifi cance was defi ned as p<0·05.
Role of the funding source
The sponsors of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the report. The corresponding author had full access to all the data in the study and had fi nal responsibility for the decision to submit for publication.
Results
164 patients with MS and 60 healthy controls participated in the study (fi gure 1, table 1). Mean follow-up durations were 25·8 (SD 9·1) months for the MS cohort and 22·4 (11·4) months for the control group. MMO was identifi ed in ten of 164 patients with MS during the study (6%; four of ten had MMO at baseline), and was bilateral in two patients (fi gure 2). In one of these patients with bilateral MMO, bilateral epiretinal membranes, without associated retinal traction, were also present (epiretinal membranes with retinal traction can appear similar to MMO on OCT images, whereas those without retinal traction do not). Epiretinal membranes, again without associated retinal traction, were identifi ed in an additional four patients with MS (fi ve eyes) without MMO, including one patient with a previous history of uveitis ipsilateral to the epiretinal membranes (no other patients in the study had a history of symptomatic uveitis). Three patients were determined in retrospect to have non-microcystic retinal pathology on OCT and were excluded from subsequent analyses (fi gure 1). The eyes of healthy controls did not show any qualitative OCT abnormalities, including MMO, during the study.
Only one patient with MMO was exposed to fi ngolimod (a known cause of macular oedema) during the study, although in this patient (identifi ed in retrospect) bilateral MMO was already evident on OCT, before the exposure (fi gure 2). Fingolimod treatment was discontinued after 2·5 months because of bilateral visual blurring. Extensive retinal assessment revealed bilateral perivascular sheathing and diff use bilateral fl uorescein leakage on fl uorescein angiography. These fi ndings persisted 1 year after visible resolution of the MMO, and despite the short exposure to fi ngolimod. A complete list of diseasemodifying therapies patients were receiving at baseline in the MS cohort (including those with and without MMO) is shown in the appendix. Detailed ophthalmological examination (including fl uorescein angiography) was done in two additional patients with MMO and was normal in both cases.
Generally, the distribution of MMO was patchy, and predominantly localised to the INL, although in three eyes microcysts were additionally present in the ONL. MMO was dynamic over time: fi ve eyes had fl uctuating MMO (ie, improving and then worsening, or vice versa), four eyes had worsening MMO, and three eyes had improving MMO (fi gure 2).
Of ten patients with MMO at any time during the study, only four had visible MMO at baseline, and in fi ve of the remaining six patients, the MMO did not become visible during 1 year of follow-up. Despite this fi nding, all patients who had MMO (regardless of the stage in the study at which the MMO fi rst became evident) had signifi cantly higher baseline (beginning of the study) MSSS compared with patients without MMO at any stage in the study (p=0·032; table 2). Similarly, eyes with MMO at any time during the study (regardless of the stage in the study at which the MMO fi rst became evident) had signifi cantly lower high-contrast and low-contrast letteracuity scores, decreased GCIP thickness, and increased INL thickness at baseline relative to MS eyes without MMO at any stage in the study ( 
Baseline clinical and radiological characteristics
Optic neuritis 83 (34%)
Baseline gadolinium-enhancing lesions* 14 (18%) 0 (0%) 0 (0%) ·· for greater inter-subject variation of INL thicknesses early in the disease course was visible and Levene's variance ratio testing showed that INL thicknesses in patients who had MS for less than 20 years versus those who had the disease for 20 years or more had signifi cantly greater variance (p=0·009).
Clinical and radiological characteristics at follow-up
2: Comparison of baseline demographics and clinical characteristics between patients with MS and MMO and those without MMO during the study
Discussion
Our study confi rms the occurrence of MMO (predominantly of the INL) in patients with MS, shows that MMO is a dynamic process, and highlight MMO as a pathological process that does not seem to occur in healthy controls. 19 Although only four of the ten patients with MS and MMO at any stage during the study had visible MMO at baseline, baseline INL thickness was higher in the patients with MS and MMO than in patients with MS who did not have MMO. This fi nding highlights the potential for earlier and broader identifi cation of this process with OCT seg mentation, even when MMO has not become visible. INL thickness in patients with RRMS was also higher than in healthy controls, suggesting 
Data are mean (SD Although the pathobiology underlying MMO or increased INL thickness in patients with MS remains unclear, an infl ammatory cause seems plausible; this could be related to subclinical uveitis or retinal periphlebitis, which could be confused with optic neuropathy, espe cially in the absence of comprehensive ophthalmological assessment. The plexiform layers surrounding the INL contain the primary networks of retinal microglia 22 and act as diff usion barriers, making the INL susceptible to fl uid accumulation during infl ammation. Consistent with an infl ammatory cause, increased INL thickness at baseline in patients with MS predicted infl ammatory disease activity. INL swelling was also most striking in patients with RRMS, and earlier in the disease, during which MS tends to be most infl ammatory. Conversely, INL neuronal degeneration and loss could predominate later in the disease course, 5, 6, 11 although a prospective longitudinal study is needed to assess whether this is the case.
Another factor that might be relevant to our fi ndings is that about 50% of patients with MS (and no healthy controls) harbour anti-KIR4.1 antibodies. 23 KIR4.1 is a potassium channel expressed on Müller glia, located in the INL, and is thought to play an important part in regulation of water fl uxes in the retina. Additionally, dysregulated KIR4.1-mediated potassium conductance in Müller cells is implicated in impaired water transport by these cells and formation of macular oedema in several ocular dis orders. 24 Accordingly, a potential relation between MMO and anti-KIR4.1 antibodies in patients with MS warrants further exploration. About 25% of patients with macular oedema who also show diff use fl uorescein leakage have INL microcysts on OCT, 25 further supporting an infl ammatory cause. Indeed, fl uorescein angiography revealed bilateral leakage in one of the patients with bilateral MMO in this study, which persisted for more than a year after visible resolution of the MMO, suggesting that MMO might not be visible in the face of ongoing infl ammation, and highlighting the potential usefulness of measuring INL thicknesses. Additionally, this patient had bilateral venous sheathing due to retinal periphlebitis. 26 Although this patient was exposed to fi ngolimod (which can cause macular oedema), 27 this drug was thought to be noncontributory since the exposure was short (2·5 months) and the MMO occurred before exposure.
During acute optic neuritis, the blood-retina barrier is susceptible to breakdown, as shown by fl uorescein leakage and features of uveitis in about 25% of patients. 28 This susceptibility could explain the tendency for increased INL thicknesses and MMO to occur in the eyes of patients with a history of optic neuritis. 19 Alternatively, INL aber rations could represent sequelae of retrograde transsy naptic de generation (instigated by demyelination in the myelinated portions of the optic nerve). 29 Longitudinal observational studies might be needed to identify such retrograde transynaptic degeneration. Careful assess ment of MMO in other optic neuropathies will be important for the investigation of retrograde transsy naptic processes. MMO and increased thickness of the INL in patients with MS might not be related to the MS disease process, but rather could be due to concomitant pathology (such as hypertension and diabetes mellitus) or a drug that might be independently associated with increased MS disease activity and the development of macular oedema. 30 This eff ect seems unlikely, however, since patients with MS and known diabetes or uncontrolled hypertension were excluded, and no such drugs were identifi ed in this study. Alternatively, MMO and increased thickness of the INL could be due to an MS-related autoimmune disorder targeting the retina.
Our study had several limitations. Although detailed ophthalmological assessment, including fl uorescein angiography, was done in a subset of patients with MMO, these assessments were not done systematically, as cases were identifi ed retrospectively. Systematic longitudinal ophthalmological assessment is needed in future studies to confi rm an infl ammatory versus non-infl ammatory cause of INL aberrations in patients with MS. Since most patients had RRMS, more accurate characterisation of this potential novel retinal phenotype by MS subtype is warranted, which will require the enrolment of larger numbers of patients with RRMS, SPMS, and PPMS, and also healthy controls. Although the controls in our study had a similar range of ages compared with patients with RRMS, the enrolment of older controls age-matched to patients with SPMS and PPMS, as well as RRMS, is needed in future studies. Since controls underwent OCT annually, and patients with MS underwent OCT every 6 months, less frequent imaging among healthy controls could have impeded detection of MMO in this group. In future studies healthy controls should undergo OCT as often as patients with MS.
Longitudinal studies of acute optic neuritis are warranted to characterise the relation between optic neuritis and MMO and increased INL thickness. Since we did not have a validation cohort, our fi ndings need to be recapitulated in other MS cohorts and with other OCT devices and OCT segmentation techniques. The microcysts recorded in this study were predominantly located in the layer we measured as the INL plus the outer plexiform layer; since INL pathology has been shown to occur in patients with MS whereas outer plexiform layer pathology has not, we strongly suspect that increased
Panel: Research in context
Systematic review
We searched PubMed for articles published in English between June 1, 1960, and June 1, 2012, with the search terms "multiple sclerosis" and "inner nuclear layer" that describe assessment of the inner nuclear layer (INL) in multiple sclerosis (MS). Nine studies were identifi ed, of which one was a large end-of-life ocular pathology study in patients with MS. 11 That study showed qualitative atrophy of the INL in over 40% of the eyes of patients with MS, as well as the presence of activated microglia in the retina of eyes of patients with MS at the end of life. In the remaining eight studies, optical coherence tomography (OCT) was used for the in-vivo assessment of the INL in patients with MS (fi ve of these studies were published by our group). 5, 6, [31] [32] [33] Using segmentation techniques to quantitatively assess the INL, two studies showed decreased thicknesses of the INL in some eyes of patients with MS, 5, 6 and one study showed decreased thickness of the INL across a cohort of patients with primary progressive MS, relative to healthy controls. 34 Two studies reported that aberrations in the thickness of the INL were not the derivative of acute optic neuritis in patients with MS. 31, 35 In two studies, signifi cant diff erences in INL thickness between patients with MS and healthy controls were not detected, 32, 33 although in one of these studies there was a non-signifi cant suggestion that the thickness of the INL across a large cohort of patients with MS might be higher than in healthy controls. 33 Finally, a recent study identifi ed and described microcystic macular oedema (MMO) of the INL in the eyes of some patients with MS, 19 which was thought to represent breakdown of the blood-retina barrier and retinal infl ammation. OCT segmentation techniques were not used in this study to assess the INL quantitatively. The clinical and radiological predictive use of INL thickness in MS has not been previously assessed.
Interpretation
Our fi ndings show a novel and dynamic phenotype of the unmyelinated retina in MS that is characterised by an increase of INL thickness on OCT, with or without accompanying MMO. This phenotype seems to be associated with later infl ammatory disease activity and with relapses, new T2 lesions, new gadolinium-enhancing lesions, and disability progression. Our fi ndings raise the possibility that infl ammation compartmentalised to the neuronal INL of the retina could be operative in MS, and that myelin might not be necessary for instigating or propagating the MS disease process. These fi ndings have implications for our understanding of the disease process in MS, and for guiding future research endeavours.
thicknesses of this composite measure primarily refl ect increased INL thickness. Nonetheless, the possibility of outer plexiform layer pathology cannot be excluded, which if determined to be the case would represent an equally intriguing and novel fi nding. Future advances in automated OCT segmentation algorithms aiding accurate assessment of the INL alone are needed to confi rm our fi ndings. Longitudinal studies are needed to determine whether MMO or increased INL thickness, potentially refl ecting INL infl ammation, ultimately lead to atrophy of INL or ONL. Finally, some bias in our MS cohort could exist (exemplifi ed by the high rate of disease activity in the patients with RRMS who received treatment) since our centre is a major MS referral centre. This potential source of bias could have implications for the translation of our fi ndings to smaller clinical centres.
In summary, we have identifi ed a novel retinal phenotype in patients with MS characterised by dynamic aberrations of the neuronal INL, in which high-defi nition OCT shows quantitative swelling of the INL, with or without accompanying microcysts. Our fi ndings raise the possibility that infl ammation compartmentalised to the myelin-free neuronal INL of the retina could be operative in MS, suggesting myelin might not be necessary for instigating or propagating infl ammation in patients with MS, and that the pathobiology of MS could include neuronally targeted infl ammation (panel). Moreover, this retinal phenotype seems to be associated with later infl ammatory disease activity. In this study, increased INL thickness was associated with the development of relapses, new T2 lesions, new gadolinium-enhancing lesions, and disability progression. The identifi cation of this potentially clinically relevant retinal phenotype in patients with MS could be an important step towards unravelling the elusive pathophysiology of MS, and merits further study.
